Last updated on April 2018

Conversion of in Vitro Fertilization Cycles to Intrauterine Inseminations in Patients With a Poor Ovarian Response to Stimulation


Brief description of study

The purpose of this study is to compare the efficiency of conversion to IUI and IVF in patients with a poor ovarian response to stimulation

Detailed Study Description

In 5 to 10% of in vitro fertilization (IVF) cycles, a poor response to ovarian stimulation (defined as less than 4 mature follicles) is noted, even though high doses of exogenous gonadotropins are used. To date, there is no consensus on the ideal management strategy in poor responders. There are three therapeutic options available nowadays:

  1. Oocyte retrieval is performed and the IVF cycle continued, despite the low number of mature follicles.
  2. Conversion of the IVF cycle to an intrauterine insemination (IUI), on the condition of having at least one patent fallopian tube and good semen parameters.
  3. Cancelation of the IVF cycle. In everyday practice, it is difficult for the physician to cancel the IVF cycle in the presence of 2, 3 or 4 mature follicles, especially following a lengthy stimulation.

If live birth rates were comparable between IUI and IVF, conversion to IUI would be the better option for poor responders, since it would avoid an invasive procedure (oocyte retrieval) and the associated risk of complications, and is associated with at a lower cost.

To our knowledge, no prospective randomized controlled trial comparing IVF to conversion to IUI in poor responders has been published to date. The studies published so far have been retrospective and observational, and had several methodological flaws.

Therefore, we aimed to analyze whether conversion of IVF cycles to IUI in poor responders would result in the same live birth rates as oocyte retrievals followed by embryo transfers.

Clinical Study Identifier: NCT03362489

Contact Investigators or Research Sites near you

Start Over

Pierre-Emmanuel Bouet, MD

UH Angers
Angers, France
  Connect »

Xenia Lechat, MD

Polyclinique Jean Villar
Bruges, France
  Connect »

Michaël Grynberg, MD PhD

Antoine B cl re Hospital AP-HP
Clamart, France
  Connect »

Aurore Gueniffey, MD

UH Grenoble
Grenoble, France
  Connect »

Sophie Fressard, MD

Lorient Hospital
Lorient, France
  Connect »

Blandine Courbière, MD PhD

UH La conception AP-HM
Marseille, France
  Connect »

Marie-Laure Langlois, MD

Clinique Jules Verne
Nantes, France
  Connect »

Florence Leperlier, MD

UH Nantes
Nantes, France
  Connect »

Frédéric Lamazou, MD

Clinique Pierre Cherest
Neuilly-sur-Seine, France
  Connect »

Anne Guivarc'h-Levêque, MD

Clinique Mutualiste de la Sagesse
Rennes, France
  Connect »

Mathilde Domin, MD

UH Rennes
Rennes, France
  Connect »

Anne-Cécile Vasseur, MD

Polyclinique de L'Atlantique
Saint-Herblain, France
  Connect »

olivier Pirrello, MD

UH Strasbourg
Strasbourg, France
  Connect »

Marion Cornuau, MD

UHR Tours
Tours, France
  Connect »

Catherine Morinière, MD

UH Pointe- -Pitre
Pointe-à-Pitre, France
  Connect »

Claudine Vasseur, MD

Clinique L onard de Vinci
Chambray-lès-Tours, France
  Connect »

Nathalie Massin, MD

IHC Cr teil
Créteil, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.